Organigram Holdings Inc. (TSE:OGI – Free Report) – Stock analysts at Atb Cap Markets issued their Q4 2025 earnings per share (EPS) estimates for Organigram in a research report issued on Wednesday, December 18th. Atb Cap Markets analyst F. Gomes forecasts that the company will earn ($0.01) per share for the quarter. The consensus estimate for Organigram’s current full-year earnings is $0.16 per share.
Several other research analysts also recently commented on OGI. Canaccord Genuity Group lowered their target price on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research note on Monday, December 9th. ATB Capital lowered their price objective on shares of Organigram from C$5.25 to C$3.50 in a research report on Tuesday.
Organigram Price Performance
Organigram stock opened at C$2.09 on Friday. The stock has a fifty day moving average of C$2.26 and a 200-day moving average of C$2.30. The stock has a market capitalization of C$226.91 million, a P/E ratio of -0.83, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. Organigram has a 52 week low of C$1.61 and a 52 week high of C$3.95.
Insiders Place Their Bets
In other news, Senior Officer Paolo De Luca sold 12,014 shares of Organigram stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. Insiders own 31.32% of the company’s stock.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Articles
- Five stocks we like better than Organigram
- Buy P&G Now, Before It Sets A New All-Time High
- Beyond Reality: Investing in AR/VR Tech for Future Gains
- Investing in Construction Stocks
- Palantir’s Momentum Persists Despite Market Worries
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Ad Sales to Top $1 Trillion: 3 Stocks to Take Advantage
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.
